Why TRAX Stock Could Disrupt a $2B Market in Q4
TRAX stock analysis: 2.3x P/B discount signals 124% upside — buy or sell valuation 👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends In this deep dive, we break down First Tracks Biotherapeutics (TRAX) and the upcoming Phase 1b clinical readouts for its lead antibody candidate, ANB033, targeting celiac disease and eosinophilic esophagitis. With shares trading at a discount 2.3x Price-to-Book ratio and backed by $180 million in standalone cash, the key…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.